Oncolytic adenoviral delivery of an EGFR-targeting t-cell engager improves antitumor efficacy

Cancer Research

Volumn 77, Issue 8, 2017, Pages 2052-2063

  Fajardo, Carlos Alberto ^a   Guedan, Sonia ^b   Rojas, Luis Alfonso ^a   Moreno, Rafael ^a   Arias Badia, Marcel ^a   De Sostoa, Jana ^a   June, Carl H ^b   Alemany, Ramon ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC T LYMPHOCYTE ENGAGER ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS ICOVIR 15K; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOENGINEERING; CD3+ T LYMPHOCYTE; COCULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM; A-549 CELL LINE; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; IMMUNOLOGY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROCEDURES; RANDOMIZATION; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL LINE; VIROLOGY;

A549 CELLS; ADENOVIRIDAE; ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; FEMALE; HCT116 CELLS; HEK293 CELLS; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018811326     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1708     Document Type: Article

References (45)

1. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotech 2012;30:658-70.
2. Buijs PRA, Verhagen JHE, van Eijck CHJ, van den Hoogen BG. Oncolytic viruses: from bench to bedside with a focus on safety. Hum Vaccin Immunother 2015;11:1573-84.
3. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial Watch. OncoImmunology 2014;3:e28694.
4. Drake CG, Jaffee E, Pardoll DM. Mechanisms of Immune Evasion by Tumors. Advances in immunology. Volume 90: Academic Press; 2006. p51-81.
5. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014;14:559-67.
6. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 2010;21:439-50.
7. Rodriguez-Garcia A, Svensson E, Gil-Hoyos R, Fajardo CA, Rojas LA, Arias-Badia M, et al. Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther 2015;22:596-601.
8. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956;9:1211-18.
9. Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Chapter Eight-Oncolytic Adenoviruses for Cancer Immunotherapy: Data fromMice, Hamsters, and Humans. In:David TC, Paul BF, editors. Advances in cancer research. Volume 115: Academic Press; 2012. p265-318.
10. de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther 2015;15:959-71.
11. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11:22-30.
12. KlingerM, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE® antibody constructs-past developments and future directions. Immunol Rev 2016;270:193-208.
13. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17:385-92.
14. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song X-T. T-cell engagerarmed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014;22:102-11.
15. Nettelbeck DM. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med 2008;86:363-77.
16. New Drugs/Drug News. Pharmacy and Therapeutics2014;39:733-85.
17. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013;24:717-27.
18. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci 2009;106:3360-5.
19. Rojas JJ, Gimenez-Alejandre M, Gil-Hoyos R, Cascallo M, Alemany R. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther 2012;19:453-7.
20. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A, et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 2009;20:1214-21.
21. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. Reengineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 2008;45:659-62, 64-8.
22. Puig-Saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther 2014;21:767-74.
23. Gros A,Martínez-Quintanilla J, Puig C, Guedan S,Molleví DG, Alemany R, et al. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 2008;68:8928-37.
24. Maizel JV, White DO, Scharff MD. The polypeptides of adenovirus. Virology 1968;36:115-25.
25. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010;18:1960-71.
26. Puig-Saus C, Laborda E, Rodriguez-Garcia A, Cascallo M, Moreno R, Alemany R. The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther 2014;21:68-73.
27. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807.
28. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007;44:1935-43.
29. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
30. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
31. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
32. Lutterbuese R, Raum T, Kischel R, Hoffmann P,Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRASand BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci 2010;107: 12605-10.
33. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154-7.
34. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/ CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-33.
35. Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 2015;23:1630-40.
36. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008;16:1609-16.
37. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012;122: 359-67.
38. Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. OncoImmunology 2016;5:e1105429.
39. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008;60:439-47.
40. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-71.
41. Schmittnaegel M, Levitsky V, Hoffmann E, Georges G, Mundigl O, Klein C, et al. Committing cytomegalovirus-specific CD8 T cells to eliminate tumor cells by bifunctional major histocompatibility class I antibody fusion molecules. Cancer Immunol Res 2015;3:764-76.
42. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18:1275-83.
43. Warnders FJ, Waaijer SJH, Pool M, Lub-de Hooge MN, Friedrich M, Terwisscha van Scheltinga AGT, et al. Biodistribution and PET imaging of labeled bispecific T cell-engaging antibody targeting EpCAM. J Nucl Med 2016;57:812-17.
44. Wüest T, Moosmayer D, Pfizenmaier K. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol 2001; 92:159-68.
45. Engler H, Machemer T, Philopena J, Wen S-F, Quijano E, Ramachandra M, et al. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-a;. Virology 2004;328:52-61.